Clinical trial
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients
NCT01002248 is registered in ClinicalTrials.gov with AEterna Zentaris as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients
- Lead sponsor
- AEterna Zentaris
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- December 31, 2009
- Completion date
- March 31, 2013
- Enrollment
- 135 (actual)
- Sites
- 86
Conditions
As the registry lists them; a condition with its own page is linked.